BGB-B2033, a bispecific antibody, targets 4-1BB and GPC3, showing potential in advanced hepatocellular carcinoma (HCC) ...

MDSCs, myeloid-derived suppressor cells; ILCs, Innate lymphoid cells; NK2, Natural killer; Th2, T helper 2; Treg, regulatory T cells; NKT, natural killer T. Hepatocellular carcinoma (HCC) is a primary ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation ...

Recurrence beyond Milan criteria predicts worse outcomes after hepatocellular carcinoma resection. Limited recurrence remains ...

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, driven by marked molecular and clinical heterogeneity and ...

Prevention and treatment advances are reducing the number of new liver cancer patients and narrowing survival gaps among racial groups, a Cedars-Sinai Cancer study published in the journal Clinical ...

Due to the extremely rare overlap of mitochondrial DNA depletion syndrome type 3 and pediatric hepatocellular carcinoma, the case presents daunting therapeutic challenges.

Hepatocellular carcinoma (HCC) is a common cancer, and the body’s immune responses greatly affect its progression and the prognosis of patients. Immunological suppression and the maintenance of ...